A clinical study of incidence of urolithiasis associated with topiramate in patients with epilepsy_Journal of Epilepsy

Authors：

 ZHANGSuojuan ^1,2 , CAOHua ¹ ,  SONGFan ¹

1. Department of Neurology, First Hospital Affiliated to Dalian Medical University, Dalian 11601, Liaoning, China;
2. Department of Neurology, People's Hospital of Huanren county, Huanren 117200, Liaoning, China;

Corresponding author：

SONGFan, Email: songfandalian@163.com

Keywords：

Epilepsy; Topiramate; Urolithiasis; Risk factors

DOI：

10.7507/2096-0247.20160006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze prospective incidence and risk factors of urolithiasis after Topiramate (TPM) therapy in epileptic patients. Methods We prospectively analyzed the incidence of urolithiasis in 120 patients with epilepsy who diagnosed in the Department of Neurology of the First Hospital Affiliated to Dalian Medical University from March 2004 to March 2013. Then calculated the incidence of urolithiasis, and analyzed the risk factors. Results In the 120 cases we collected, male accounted for 74, female accounted for 46. After treated with TPM, the incidence of urolithiasis was 18.3%. All of urolithiasis were kidney stones. The stones caused by TPM were mostly single and small, most of which would disappear spontaneously after discontinuation of the medication. The incidence of asymptomatic urolithiasis was 3.4 times to that of symptomatic urolithiasis. The development of urolithiasis had no correlation with the dose of TPM and duration. Urolithiasis frequently occurred in epilepsy patients in the age over 20 or symptomatic epilepsy or duration of combined medication≥3 months. Conclusions The incidence of urolithiasis in epilepsy patients was 18.3% after initiating TPM therapy. The stones would disappear spontaneously after discontinuation of the medication. The development of urolithiasis had no correlation with the dose of topiramate and duration.

Citation： ZHANGSuojuan, CAOHua, SONGFan. A clinical study of incidence of urolithiasis associated with topiramate in patients with epilepsy. Journal of Epilepsy, 2016, 2(1): 30-33. doi: 10.7507/2096-0247.20160006 Copy

1.	Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia, 1996, 37 (Suppl 2): 18-22.
2.	Hu Y, Lu Y, Yu W, et al. Long-term retention rate of topiramate as initial monotherapy in Chinese patients with newly diagnosed epilepsy: a prospective, observational study. Epilepsy Res, 2010, 90(3): 278-284.
3.	Maalouf NM, Langston JP, Van Ness PC, et al. Nephrolithiasis in topiramate users. Urological Research, 2011, 39(4): 303-307.
4.	Nicol CB, Twombley K, Ahn J, et al.Prevalence and spot urine risk factors for renal stones in children taking topiramate. Pediatric Urol, 2013, 9(6): 884-889.
5.	Eggener S, Kim SC, Pazona J, et al. Urolithiasis associated with topiramate. International Braz J Urol, 2004, 30(1): 29-31.
6.	Goyal M, Grossberg RI, O'Riordan MA, et al. Urolithiasis with topiramate in nonambulatory children and young adults. Pediatric Neurology, 2009, 40(4): 289-294.
7.	Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. American Journal of Kidney Diseases, 2006, 48(4): 555-563.
8.	Kaplon DM, Penniston KL, Nakada SY. Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Urology, 2011, 77(2): 295-298.
9.	孙海鸥, 胡伟新.药物性肾损害的机制及其临床表现.肾脏病与透析肾移植杂志, 2006, 15(3): 252-257.
10.	Warner BW, LaGrange CA, Tucker T, et al. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology, 2008, 72(1): 29-32.
11.	Michael MJ. Safety of topiramate for treating migraines. Expert Opinion on Drug Safety, 2014, 13(9): 1241-1247.

1. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia, 1996, 37 (Suppl 2): 18-22.
2. Hu Y, Lu Y, Yu W, et al. Long-term retention rate of topiramate as initial monotherapy in Chinese patients with newly diagnosed epilepsy: a prospective, observational study. Epilepsy Res, 2010, 90(3): 278-284.
3. Maalouf NM, Langston JP, Van Ness PC, et al. Nephrolithiasis in topiramate users. Urological Research, 2011, 39(4): 303-307.
4. Nicol CB, Twombley K, Ahn J, et al.Prevalence and spot urine risk factors for renal stones in children taking topiramate. Pediatric Urol, 2013, 9(6): 884-889.
5. Eggener S, Kim SC, Pazona J, et al. Urolithiasis associated with topiramate. International Braz J Urol, 2004, 30(1): 29-31.
6. Goyal M, Grossberg RI, O'Riordan MA, et al. Urolithiasis with topiramate in nonambulatory children and young adults. Pediatric Neurology, 2009, 40(4): 289-294.
7. Welch BJ, Graybeal D, Moe OW, et al. Biochemical and stone-risk profiles with topiramate treatment. American Journal of Kidney Diseases, 2006, 48(4): 555-563.
8. Kaplon DM, Penniston KL, Nakada SY. Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Urology, 2011, 77(2): 295-298.
9. 孙海鸥, 胡伟新.药物性肾损害的机制及其临床表现.肾脏病与透析肾移植杂志, 2006, 15(3): 252-257.
10. Warner BW, LaGrange CA, Tucker T, et al. Induction of progressive profound hypocitraturia with increasing doses of topiramate. Urology, 2008, 72(1): 29-32.
11. Michael MJ. Safety of topiramate for treating migraines. Expert Opinion on Drug Safety, 2014, 13(9): 1241-1247.

Previous Article
Genetic characteristics of SCN1A mutations in 547 Dravet syndrome
Next Article
The dynamic expression of Robo3 in the hippocampus of the lithium-pilocarpine induced rat model

Journal of Epilepsy

A clinical study of incidence of urolithiasis associated with topiramate in patients with epilepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content